phenyl butazone

General Material Information

Preferred name	phenyl butazone
Trivial Name	Phenylbutazone
Short Description	4-butyl-1,2-diphenylpyrazolidine-3,5-dione
Formula	C19 H20 N2 O2
CAS Number	50-33-9
Deleted CAS Number	4297-92-1
ECHA Number	200-029-0
FDA UNII	GN5P7K3T8S
Nikkaji Number	J792G
Beilstein Number	0290080
MDL	MFCD00005500
Bio Activity Summary	External link
NMR Predictor	External link
Synonyms	1,2-diphenyl-2,3-dioxo-4-N-butylpyrazoline 1,2-diphenyl-3,5-dioxo-4-butylpyrazolidine 1,2-diphenyl-3,5-dioxo-4-N-butylpyrazoline 1,2-diphenyl-4-butyl-3,5-dioxopyrazolidine 1,2-diphenyl-4-butyl-3,5-pyrazolidinedione 3,5-dioxo-1,2-diphenyl-4-N-butylpyrazolidine 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine 3,5-pyrazolidinedione, 4-butyl-1,2-diphenyl- 4-butyl-1,2 -diphenyl-3,5-dioxo pyrazolidine 4-butyl-1,2-diphenyl-1,2-diazolidine-3,5-dione 4-butyl-1,2-diphenyl-3,5-dioxopyrazolidine 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione 4-butyl-1,2-diphenyl-pyrazolidine-3,5-dione 4-butyl-1,2-diphenylpyrazolidine-3,5-dione 4-N- butyl-1,2-diphenyl-3,5-pyrazolidinedione mepha-butazon phenbutazone phenylbutazone phenylbutazonum phenyzene pyrasanone pyrazinobutazone ranoroc shigrodin tencodyne tetnor tevcodyne therazone ticinil todalgil zolidinum 3,5-Pyrazolidinedione, 4-butyl-1,2-diphenyl- 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione G 13,871 Artrizin Butalidon Butapirazol Butazolidin Butazolidine Butidiona 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione 3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidine Diphebuzol Diphenylbutazone 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione Fenibutazona Phebuzine Pirarreumol B Reudo Reudox Reumuzol Butadion Butadione VAC-10 Pyrabutol 1,2-Diphenyl-3,5-dioxo-4-n-butylpyrazolidine 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine Fenylbutazon Alindor Flexazone Ia-But Antadol Buzon R-3-ZON Anuspiramin Ecobutazone Fenotone Bunetzone Fenilbutina Zolaphen Azolid Betazed Benzone Butoz Butacote Fenibutal Robizone Mephabutazon Bizolin 200 Uzone 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione Butartrina Butazina Arthrizon Reumazin Artropan Kadol Butapirazole Equipalazone Phenylbutazon Alkazone NSC 25134 Butatron Phen-Buta MeSH ID: D010653

US / EU / FDA / JECFA / FEMA / Scholar / Patents

Google Scholar	Start search
Google Books	Start search
Google Patents	Start search
Perfumer & Flavorists	Start search
EU Patents	Start search
PubMeb	Start search
NCBI	Start search

Literature & References

	4-butyl-1,2-diphenylpyrazolidine-3,5-dione
NIST Chemistry WebBook:	Search Inchi
Canada Domestic Sub. List:	50-33-9
Pubchem (cid):	4781
Pubchem (sid):	134971182

Publications by Info
Phenylbutazone
Publications by PubMed
Veterinary drug residues in domestic and imported foods of animal origin in the Republic of Korea.
Investigation into sources of contamination of cattle with phenylbutazone.
Pharmacokinetics, pharmacodynamics, metabolism, toxicology and residues of phenylbutazone in humans and horses.
Bute residues of low concern for consumers, say EFSA and EMA.
EC seeks advice on risks from phenylbutazone in horsemeat.
"Bute" in horse meat presents very low risk to health, says England's chief medical officer.
Development and validation of two multiresidue liquid chromatography tandem mass spectrometry methods based on a versatile extraction procedure for isolating non-steroidal anti-inflammatory drugs from bovine milk and muscle tissue.
Food and Chemical Toxicology, 2010, Association of phenylbutazone usage in horses bought for slaughter: a public health risk.
Development and validation of a confirmatory method for the determination of 12 non steroidal anti-inflammatory drugs in milk using liquid chromatography-tandem mass spectrometry.
Quantification of anthelmintic drug residues in milk and muscle tissues by liquid chromatography coupled to Orbitrap and liquid chromatography coupled to tandem mass spectrometry.
Simultaneous determination of 20 pharmacologically active substances in cow's milk, goat's milk, and human breast milk by gas chromatography-mass spectrometry.
Surveillance study of novobiocin and phenylbutazone residues in raw bovine milk using liquid chromatography-tandem mass spectrometry.
Identification of the human UDP-glucuronosyltransferases involved in the glucuronidation of combretastatin A-4.
Association of phenylbutazone usage with horses bought for slaughter: a public health risk.
A survey on two years of medication regulation in horse races in Iran.
Multicentre, controlled, randomised and blinded field study comparing efficacy of suxibuzone and phenylbutazone in lame horses.
Interaction of polyphenolic metabolites with human serum albumin: a circular dichroism study.
Determination of ibuprofen, ketoprofen, diclofenac and phenylbutazone in bovine milk by gas chromatography-tandem mass spectrometry.
An update on nonsteroidal anti-inflammatory drugs (NSAIDs) in small animals.
Extralabel use of nonsteroidal anti-inflammatory drugs in cattle.
Confirmatory identification of sixteen non-steroidal anti-inflammatory drug residues in raw milk by liquid chromatography coupled with ion trap mass spectrometry.
Surveillance for selected bacterial and toxicologic contaminants in donated carcass meat fed to carnivores.
Use of accelerating solvent extraction for detecting non-steroidal anti-inflammatory drugs in horse feces.
Left otitis media/interna and right maxillary sinusitis in a Percheron mare.
Comparison of the effect of Sporobolus virginicus and Rhodes (Chloris gayana) hay diets on the absorption pattern of phenylbutazone in the camel (Camelus dromedarius).
Multi-residue liquid chromatography/tandem mass spectrometry method for the detection of non-steroidal anti-inflammatory drugs in bovine muscle: optimisation of ion trap parameters.
Ornithine transcarbamylase deficiency: a urea cycle defect.
Preliminary studies of offspring exposure to phenylbutazone and ivermectin during the perinatal period in a Holstein cow-calf model.
Pharmacokinetics of phenylbutazone in beef steers.
Late diagnosis of ornithine transcarbamylase defect in three related female patients: polymorphic presentations.
Determination of non-protein bound phenylbutazone in bovine plasma using ultrafiltration and liquid chromatography with ultraviolet detection.
Pharmacokinetics of phenylbutazone in plasma and milk of lactating dairy cows.
Ancillary therapy of bovine respiratory disease.
Extralabel use of nonsteroidal anti-inflammatory drugs.
Effect of evening primrose oil on gastric ulceration and secretion induced by various ulcerogenic and necrotizing agents in rats.
Determination of phenylbutazone residues in bovine milk by liquid chromatography with UV detection.
[The concentration changes of different phenylbutazone formulations in horse plasma].
Interactions of warfarin with drugs and food.
Norplant: a welcome new contraceptive.
Subdermal contraceptive implants in nurse-midwifery practice.
Use of nonsteroidal anti-inflammatory drugs in food animal practice.
Contact sensitivity to pyrazinobutazone (Carudol) with positive oral provocation test.
Chemicals and drugs as triggers of food-associated disorder.
Experimental renal papillary necrosis in the Syrian hamster.
Experimental uses of flunixin meglumine and phenylbutazone in food-producing animals.
[The pathogenetic significance of prostaglandins in food poisoning and therapy questions].
Effects of anti-inflammatory analgesic drugs and muscarinic receptor blocking agents on appetite in the pig.
Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse.
Risks and indications of phenylbutazone: another look.
Lack of effect of non-steroid antiinflammatory drugs on lithium clearance and on delivery of tubular fluid to the loop of Henle in rats.
Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies.
Genetic and histological aspects of stomach lesions induced by systemic injection of phenylbutazone in the rat.
Interactions of analgesics with other drugs.
The effect of food on the absorption of phenylbutazone from a commercial 100 mg enteric-coated tablet.
Effect of Tomanol on the pharmacokinetics and tissue distribution of penicillin G in dairy cows.
Chemically induced leukemia in humans.
Therapeutic implications of drug interactions with acetaminophen and aspirin.
Evidence for in vitro and in vivo interaction between ochratoxin A and three acidic drugs.
Research review. Interactions between environmental chemicals and drug biotransformation in man.
[Induction of cleft palate in ball mice: the comparative effect of 5-fluorouracil, phenylbutazone and water and food deprivation (author's transl)].
Discriminative stimulus properties of analgesic drugs: narcotic versus non-narcotic analgesics.
Further studies on self-administration of antipyretic analgesics and combination of antipyretic analgesics with codeine in rhesus monkeys.
Effects of benzoquinolizine homologues on proliferative and exudative inflammation.
Indomethacin-induced intestinal lesions in the rat.
Pharmacological studies of a new anti-inflammatory drug, 1-phenylsulfonyl-5,5-diphenylhydantoin (PC-796) in experimental animals. II. Toxicological and general pharmacological properties.
More about isonicotinic acid hydrazide toxicity.
The biopharmaceutical properties of solid dosage forms. I. An evaluation of 23 brands of phenylbutazone tablets.

Other Information

(IUPAC):	Atomic Weights of the Elements 2011 (pdf)
Videos:	The Periodic Table of Videos
tgsc:	Atomic Weights use for this web site
(IUPAC):	Periodic Table of the Elements
CHEBI:	View
CHEMBL:	View
KEGG (GenomeNet):	C07440
HMDB (The Human Metabolome Database):	Search
Export Tariff Code:	2933.19.4000
MedlinePlusSupp:	View
ChemSpider:	View
Wikipedia:	View
Formulations/Preparations: •phenylbutazone tablets containing 100 mg and 1000 mg of active ingredient are available for oral administration to dogs and horses, respectively, for treatment of inflammation associated with the musculoskeletal system. phenylbutazone solution for intravenous injection contains 200 mgml of active ingredient and is indicated for the relief of inflammation associated with the musculoskeletal system of the horse. •grade: national formulary •oral capsules, 100 mg; phenylbutazone capsules, barr, cmc, interstate, major, rugby; tablets film-coated, 100 mg; phenylbutazone tablets, barr, cmc, interstate, major, rugby, united research.

Suppliers

BOC Sciences	Glentham Life Sciences
Santa Cruz Biotechnology	Sigma-Aldrich: Sigma
Glentham Life Sciences Ltd

PhysChem Properties

Material listed in food chemical codex	No
Molecular weight	308.38079833984
Vapor Pressure	6.38 mmHg @ 25 °C
Flash Point TCC Value	174.3 °C TCC
logP (o/w)	3.16
Solubility
water, 47.5 mg/L @ 30 °C (exp)	Yes
water, 21.95 mg/L @ 25 °C (est)	Yes

Safety Information

Safety information

Preferred SDS: View

Hazards identification

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements

Pictogram

Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
intravenous-cat LD50 100 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 36, 1969. intravenous-dog LD50 121 mg/kg BEHAVIORAL: ANALGESIA Archives Internationales de Pharmacodynamie et de Therapie. Vol. 149, Pg. 571, 1964. oral-dog LD50 332 mg/kg BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 265, 1980. oral-guinea pig LD50 250 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 1207, 1969. oral-hamster LD50 1260 mg/kg Archives of Toxicology, Supplement. Vol. 7, Pg. 365, 1984. intraperitoneal-mammal (species unspecified) LD50 300 mg/kg BEHAVIORAL: ANALGESIA European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 21, Pg. 277, 1986. oral-mammal (species unspecified) LD50 700 mg/kg BEHAVIORAL: ANALGESIA European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 21, Pg. 277, 1986. oral-man TDLo 17500 ug/kg/3W KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED Annals of Internal Medicine. Vol. 41, Pg. 1075, 1954. oral-man TDLo 2426 mg/kg/24H LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD Annals of Emergency Medicine. Vol. 20, Pg. 204, 1991. unreported-man TDLo 200 mg/kg/5W-I KIDNEY, URETER, AND BLADDER: HEMATURIA KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION British Medical Journal. Vol. 282, Pg. 950, 1981. intramuscular-mouse LD50 430 mg/kg BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) Oyo Yakuri. Pharmacometrics. Vol. 13, Pg. 97, 1977. intraperitoneal-mouse LD50 128 mg/kg Pharmaceutical Chemistry Journal Vol. 19, Pg. 33, 1985. intravenous-mouse LD50 90 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 36, 1969. oral-mouse LD50 238 mg/kg Pharmacological Research Communications. Vol. 18, Pg. 241, 1986. unreported-mouse LD50 128 mg/kg Farmatsevtichnii Zhurnal Vol. (5), Pg. 26, 1983. intravenous-rabbit LD50 146 mg/kg BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 129, 1960. oral-rabbit LD50 781 mg/kg BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 265, 1980. intramuscular-rat LD50 220 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 665, 1960. intraperitoneal-rat LD50 142 mg/kg Farmaco, Edizione Scientifica. Vol. 14, Pg. 347, 1959. intravenous-rat LD50 100 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 665, 1960. oral-rat LD50 245 mg/kg BEHAVIORAL: ANALGESIA Archives Internationales de Pharmacodynamie et de Therapie. Vol. 123, Pg. 48, 1959.
Dermal Toxicity:
subcutaneous-mouse LD50 230 mg/kg Journal of Pharmacy and Pharmacology. Vol. 7, Pg. 1022, 1955. subcutaneous-rat LD50 230 mg/kg BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 1285, 1972.
Inhalation Toxicity:
Not determined

Safety in use information

Category:
pharmaceuticals / chemical synthisis
Recommendation for phenyl butazone usage levels up to:
	not for fragrance use.

Recommendation for phenyl butazone flavor usage levels up to:
	not for flavor use.